Profiles of basal and stimulated receptor signaling networks predict drug response in breast cancer lines

Science Signaling

Volumn 6, Issue 294, 2013, Pages

  Niepel, Mario ^a   Hafner, Marc ^a   Pace, Emily A ^b   Chung, Mirra ^a   Chai, Diana H ^b   Zhou, Lili ^a   Schoeberl, Birgit ^b   Sorger, Peter K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MERRIMACK PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 9 (1 ANILINOETHYL) 7 METHYL 2 MORPHOLINOPYRIDO[1,2 A]PYRIMIDIN 4 ONE; A 6730; AFATINIB; BOSUTINIB; ERLOTINIB; GEFITINIB; GROWTH FACTOR RECEPTOR; GSK 1059615; GSK 1070916; GSK 2119563; GSK 2126458; GSK 461364; LAPATINIB; LIGAND; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NEU DIFFERENTIATION FACTOR; OXAMFLATIN; PANOBINOSTAT; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; RAPAMYCIN; SELUMETINIB; TCS 2312; TEMSIROLIMUS; TRAMETINIB; TRASTUZUMAB; TRICIRIBINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ARTICLE; BASAL CELL; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER CLASSIFICATION; CELL STIMULATION; CELL SUBPOPULATION; CELL SURVIVAL; DRUG EXPOSURE; DRUG MONITORING; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE MUTATION; GENOTYPE; HUMAN; IMMUNOASSAY; PARTIAL LEAST SQUARES REGRESSION; PRIORITY JOURNAL; PROTEIN ANALYSIS; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MUTATION; NEUREGULIN-1; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84885722700     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2004379     Document Type: Article

References (64)

1. S. A. Forbes, N. Bindal, S. Bamford, C. Cole, C. Y. Kok, D. Beare, M. Jia, R. Shepherd, K. Leung, A. Menzies, J. W. Teague, P. J. Campbell, M. R. Stratton, P. A. Futreal, COSMIC: Mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 39, D945-D950 (2011).
2. C. L. Vogel, M. A. Cobleigh, D. Tripathy, J. C. Gutheil, L. N. Harris, L. Fehrenbacher, D. J. Slamon, M. Murphy, W. F. Novotny, M. Burchmore, S. Shak, S. J. Stewart, M. Press, Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719-726 (2002).
3. M. A. Cobleigh, C. L. Vogel, D. Tripathy, N. J. Robert, S. Scholl, L. Fehrenbacher, J. M. Wolter, V. Paton, S. Shak, G. Lieberman, D. J. Slamon, Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17, 2639-2648 (1999).
4. G. Bollag, P. Hirth, J. Tsai, J. Zhang, P. N. Ibrahim, H. Cho, W. Spevak, C. Zhang, Y. Zhang, G. Habets, E. A. Burton, B. Wong, G. Tsang, B. L. West, B. Powell, R. Shellooe, A. Marimuthu, H. Nguyen, K. Y. Zhang, D. R. Artis, J. Schlessinger, F. Su, B. Higgins, R. Iyer, K. D'Andrea, A. Koehler, M. Stumm, P. S. Lin, R. J. Lee, J. Grippo, I. Puzanov, K. B. Kim, A. Ribas, G. A. McArthur, J. A. Sosman, P. B. Chapman, K. T. Flaherty, X. Xu, K. L. Nathanson, K. Nolop, Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596-599 (2010).
5. K. T. Flaherty, I. Puzanov, K. B. Kim, A. Ribas, G. A. McArthur, J. A. Sosman, P. J. O'Dwyer, R. J. Lee, J. F. Grippo, K. Nolop, P. B. Chapman, Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819 (2010).
6. M. Fukuoka, S. Yano, G. Giaccone, T. Tamura, K. Nakagawa, J. Y. Douillard, Y. Nishiwaki, J. Vansteenkiste, S. Kudoh, D. Rischin, R. Eek, T. Horai, K. Noda, I. Takata, E. Smit, S. Averbuch, A. Macleod, A. Feyereislova, R. P. Dong, J. Baselga, Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J. Clin. Oncol. 21, 2237-2246 (2003).
7. M. G. Kris, R. B. Natale, R. S. Herbst, T. J. Lynch Jr., D. Prager, C. P. Belani, J. H. Schiller, K. Kelly, H. Spiridonidis, A. Sandler, K. S. Albain, D. Cella, M. K. Wolf, S. D. Averbuch, J. J. Ochs, A. C. Kay, Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290, 2149-2158 (2003).
8. B. J. Druker, S. Tamura, E. Buchdunger, S. Ohno, G. M. Segal, S. Fanning, J. Zimmermann, N. B. Lydon, Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2, 561-566 (1996).
9. National Cancer Institute, http://www.cancer.gov/ [accessed 28 August 2013].
10. M. J. Piccart-Gebhart, M. Procter, B. Leyland-Jones, A. Goldhirsch, M. Untch, I. Smith, L. Gianni, J. Baselga, R. Bell, C. Jackisch, D. Cameron, M. Dowsett, C. H. Barrios, G. Steger, C. S. Huang, M. Andersson, M. Inbar, M. Lichinitser, I. Láng, U. Nitz, H. Iwata, C. Thomssen, C. Lohrisch, T. M. Suter, J. Rüschoff, T. Suto, V. Greatorex, C. Ward, C. Straehle, E. McFadden, M. S. Dolci, R. D. Gelber; T. Herceptin Adjuvant Trial Study, Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659-1672 (2005).
11. I. Smith, M. Procter, R. D. Gelber, S. Guillaume, A. Feyereislova, M. Dowsett, A. Goldhirsch, M. Untch, G. Mariani, J. Baselga, M. Kaufmann, D. Cameron, R. Bell, J. Bergh, R. Coleman, A. Wardley, N. Harbeck, R. I. Lopez, P. Mallmann, K. Gelmon, N. Wilcken, E. Wist, P. Sánchez Rovira, M. J. Piccart-Gebhart; HERA Study Team, 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 369, 29-36 (2007).
12. J. Baselga, K. A. Gelmon, S. Verma, A. Wardley, P. Conte, D. Miles, G. Bianchi, J. Cortes, V. A. McNally, G. A. Ross, P. Fumoleau, L. Gianni, Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J. Clin. Oncol. 28, 1138-1144 (2010).
13. L. Gianni, T. Pienkowski, Y. M. Im, L. Roman, L. M. Tseng, M. C. Liu, A. Lluch, E. Staroslawska, J. de la Haba-Rodriguez, S. A. Im, J. L. Pedrini, B. Poirier, P. Morandi, V. Semiglazov, V. Srimuninnimit, G. Bianchi, T. Szado, J. Ratnayake, G. Ross, P. Valagussa, Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 13, 25-32 (2012).
14. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365, 1687-1717 (2005).
15. International Breast Cancer Study Group, M. Colleoni, S. Gelber, A. Goldhirsch, S. Aebi, M. Castiglione-Gertsch, K. N. Price, A. S. Coates, R. D. Gelber, Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J. Clin. Oncol. 24, 1332-1341 (2006).
16. C. Liedtke, C. Mazouni, K. R. Hess, F. André, A. Tordai, J. A. Mejia, W. F. Symmans, A. M. Gonzalez-Angulo, B. Hennessy, M. Green, M. Cristofanilli, G. N. Hortobagyi, L. Pusztai, Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 26, 1275-1281 (2008).
17. M. Bernsdorf, C. Ingvar, L. Jörgensen, M. K. Tuxen, E. H. Jakobsen, A. Saetersdal, M. L. Kimper-Karl, N. Kroman, E. Balslev, B. Ejlertsen, Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial. Breast Cancer Res. Treat. 126, 463-470 (2011).
18. L. A. Carey, H. S. Rugo, P. K. Marcom, E. L. Mayer, F. J. Esteva, C. X. Ma, M. C. Liu, A. M. Storniolo, M. F. Rimawi, A. Forero-Torres, A. C. Wolff, T. J. Hobday, A. Ivanova, W. K. Chiu, M. Ferraro, E. Burrows, P. S. Bernard, K. A. Hoadley, C. M. Perou, E. P. Winer, TBCRC 001: Randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J. Clin. Oncol. 30, 2615-2623 (2012).
19. K. Chin, S. DeVries, J. Fridlyand, P. T. Spellman, R. Roydasgupta, W.-L. Kuo, A. Lapuk, R. M. Neve, Z. Qian, T. Ryder, F. Chen, H. Feiler, T. Tokuyasu, C. Kingsley, S. Dairkee, Z. Meng, K. Chew, D. Pinkel, A. Jain, B. M. Ljung, L. Esserman, D. G. Albertson, F. M. Waldman, J. W. Gray, Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10, 529-541 (2006).
20. L. M. Heiser, A. Sadanandam, W. L. Kuo, S. C. Benz, T. C. Goldstein, S. Ng, W. J. Gibb, N. J. Wang, S. Ziyad, F. Tong, N. Bayani, Z. Hu, J. I. Billig, A. Dueregger, S. Lewis, L. Jakkula, J. E. Korkola, S. Durinck, F. Pepin, Y. Guan, E. Purdom, P. Neuvial, H. Bengtsson, K. W. Wood, P. G. Smith, L. T. Vassilev, B. T. Hennessy, J. Greshock, K. E. Bachman, M. A. Hardwicke, J. W. Park, L. J. Marton, D. M. Wolf, E. A. Collisson, R. M. Neve, G. B. Mills, T. P. Speed, H. S. Feiler, R. F. Wooster, D. Haussler, J. M. Stuart, J. W. Gray, P. T. Spellman, Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc. Natl. Acad. Sci. U.S.A. 109, 2724-2729 (2012).
21. R. M. Neve, K. Chin, J. Fridlyand, J. Yeh, F. L. Baehner, T. Fevr, L. Clark, N. Bayani, J. P. Coppe, F. Tong, T. Speed, P. T. Spellman, S. DeVries, A. Lapuk, N. J. Wang, W. L. Kuo, J. L. Stilwell, D. Pinkel, D. G. Albertson, F. M. Waldman, F. McCormick, R. B. Dickson, M. D. Johnson, M. Lippman, S. Ethier, A. Gazdar, J. W. Gray, A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10, 515-527 (2006).
22. The Cancer Genome Atlas Network, Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
23. S. P. Shah, A. Roth, R. Goya, A. Oloumi, G. Ha, Y. Zhao, G. Turashvili, J. Ding, K. Tse, G. Haffari, A. Bashashati, L. M. Prentice, J. Khattra, A. Burleigh, D. Yap, V. Bernard, A. McPherson, K. Shumansky, A. Crisan, R. Giuliany, A. Heravi-Moussavi, J. Rosner, D. Lai, I. Birol, R. Varhol, A. Tam, N. Dhalla, T. Zeng, K. Ma, S. K. Chan, M. Griffith, A. Moradian, S. W. G. Cheng, G. B. Morin, P. Watson, K. Gelmon, S. Chia, S.-F. Chin, C. Curtis, O. M. Rueda, P. D. Pharoah, S. Damaraju, J. Mackey, K. Hoon, T. Harkins, V. Tadigotla, M. Sigaroudinia, P. Gascard, T. Tlsty, J. F. Costello, I. M. Meyer, C. J. Eaves, W. W. Wasserman, S. Jones, D. Huntsman, M. Hirst, C. Caldas, M. A. Marra, S. Aparicio, The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486, 395-399 (2012).
24. M. Shastry, D. A. Yardley, Updates in the treatment of basal/triple-negative breast cancer. Curr. Opin. Obstet. Gynecol. 25, 40-48 (2013).
25. D. B. Solit, L. A. Garraway, C. A. Pratilas, A. Sawai, G. Getz, A. Basso, Q. Ye, J. M. Lobo, Y. She, I. Osman, T. R. Golub, J. Sebolt-Leopold, W. R. Sellers, N. Rosen, BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358-362 (2006).
26. J. Barretina, G. Caponigro, N. Stransky, K. Venkatesan, A. A. Margolin, S. Kim, C. J. Wilson, J. Lehár, G. V. Kryukov, D. Sonkin, A. Reddy, M. Liu, L. Murray, M. F. Berger, J. E. Monahan, P. Morais, J. Meltzer, A. Korejwa, J. Jané-Valbuena, F. A. Mapa, J. Thibault, E. Bric-Furlong, P. Raman, A. Shipway, I. H. Engels, J. Cheng, G. K. Yu, J. Yu, P. Aspesi Jr., M. de Silva, K. Jagtap, M. D. Jones, L. Wang, C. Hatton, E. Palescandolo, S. Gupta, S. Mahan, C. Sougnez, R. C. Onofrio, T. Liefeld, L. MacConaill, W. Winckler, M. Reich, N. Li, J. P. Mesirov, S. B. Gabriel, G. Getz, K. Ardlie, V. Chan, V. E. Myer, B. L. Weber, J. Porter, M. Warmuth, P. Finan, J. L. Harris, M. Meyerson, T. R. Golub, M. P. Morrissey, W. R. Sellers, R. Schlegel, L. A. Garraway, The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607 (2012).
27. M. J. Garnett, E. J. Edelman, S. J. Heidorn, C. D. Greenman, A. Dastur, K. W. Lau, P. Greninger, I. R. Thompson, X. Luo, J. Soares, Q. Liu, F. Iorio, D. Surdez, L. Chen, R. J. Milano, G. R. Bignell, A. T. Tam, H. Davies, J. A. Stevenson, S. Barthorpe, S. R. Lutz, F. Kogera, K. Lawrence, A. McLaren-Douglas, X. Mitropoulos, T. Mironenko, H. Thi, L. Richardson, W. Zhou, F. Jewitt, T. Zhang, P. O'Brien, J. L. Boisvert, S. Price, W. Hur, W. Yang, X. Deng, A. Butler, H. G. Choi, J. W. Chang, J. Baselga, I. Stamenkovic, J. A. Engelman, S. V. Sharma, O. Delattre, J. Saez-Rodriguez, N. S. Gray, J. Settleman, P. A. Futreal, D. A. Haber, M. R. Stratton, S. Ramaswamy, U. McDermott, C. H. Benes, Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570-575 (2012).
28. F. Meric-Bernstam, A. Akcakanat, H. Chen, K. A. Do, T. Sangai, F. Adkins, A. M. Gonzalez-Angulo, A. Rashid, K. Crosby, M. Dong, A. T. Phan, R. A. Wolff, S. Gupta, G. B. Mills, J. Yao, PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin. Cancer Res. 18, 1777-1789 (2012).
29. M. J. Lee, A. S. Ye, A. K. Gardino, A. M. Heijink, P. K. Sorger, G. MacBeath, M. B. Yaffe, Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 149, 780-794 (2012).
30. O. K. Mirzoeva, D. Das, L. M. Heiser, S. Bhattacharya, D. Siwak, R. Gendelman, N. Bayani, N. J. Wang, R. M. Neve, Y. Guan, Z. Hu, Z. Knight, H. S. Feiler, P. Gascard, B. Parvin, P. T. Spellman, K. M. Shokat, A. J. Wyrobek, M. J. Bissell, F. McCormick, W. L. Kuo, G. B. Mills, J. W. Gray, W. M. Korn, Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res. 69, 565-572 (2009).
31. B. Bodenmiller, E. R. Zunder, R. Finck, T. J. Chen, E. S. Savig, R. V. Bruggner, E. F. Simonds, S. C. Bendall, K. Sachs, P. O. Krutzik, G. P. Nolan, Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators. Nat. Biotechnol. 30, 858-867 (2012).
32. T. R. Wilson, J. Fridlyand, Y. Yan, E. Penuel, L. Burton, E. Chan, J. Peng, E. Lin, Y. Wang, J. Sosman, A. Ribas, J. Li, J. Moffat, D. P. Sutherlin, H. Koeppen, M. Merchant, R. Neve, J. Settleman, Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487, 505-509 (2012).
33. R. Straussman, T. Morikawa, K. Shee, M. Barzily-Rokni, Z. R. Qian, J. Du, A. Davis, M. M. Mongare, J. Gould, D. T. Frederick, Z. A. Cooper, P. B. Chapman, D. B. Solit, A. Ribas, R. S. Lo, K. T. Flaherty, S. Ogino, J. A. Wargo, T. R. Golub, Tumour microenvironment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500-504 (2012).
34. K. M. Ignatoski, A. J. Lapointe, E. H. Radany, S. P. Ethier, erbB-2 overexpression in human mammary epithelial cells confers growth factor independence. Endocrinology 140, 3615-3622 (1999).
35. D. C. Gamett, G. Pearson, R. A. Cerione, I. Friedberg, Secondary dimerization between members of the epidermal growth factor receptor family. J. Biol. Chem. 272, 12052-12056 (1997).
36. R. Nahta, L. X. Yuan, B. Zhang, R. Kobayashi, F. J. Esteva, Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 65, 11118-11128 (2005).
37. J. H. Law, G. Habibi, K. Hu, H. Masoudi, M. Y. Wang, A. L. Stratford, E. Park, J. M. Gee, P. Finlay, H. E. Jones, R. I. Nicholson, J. Carboni, M. Gottardis, M. Pollak, S. E. Dunn, Phosphorylated insulin-like growth factor-I/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res. 68, 10238-10246 (2008).
38. R. Kurzrock, A. Patnaik, J. Aisner, T. Warren, S. Leong, R. Benjamin, S. G. Eckhardt, J. E. Eid, G. Greig, K. Habben, C. D. McCarthy, L. Gore, A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin. Cancer Res. 16, 2458-2465 (2010).
39. S. S. Ramalingam, D. R. Spigel, D. Chen, M. B. Steins, J. A. Engelman, C. P. Schneider, S. Novello, W. E. Eberhardt, L. Crino, K. Habben, L. Liu, P. A. Jänne, C. M. Brownstein, M. Reck, Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 29, 4574-4580 (2011).
40. K. P. Raghav, W. Wang, S. Liu, M. Chavez-MacGregor, X. Meng, G. N. Hortobagyi, G. B. Mills, F. Meric-Bernstam, G. R. Blumenschein Jr., A. M. Gonzalez-Angulo, cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin. Cancer Res. 18, 2269-2277 (2012).
41. P. M. Comoglio, S. Giordano, L. Trusolino, Drug development of MET inhibitors: Targeting oncogene addiction and expedience. Nat. Rev. Drug Discov. 7, 504-516 (2008).
42. A. N. Brooks, E. Kilgour, P. D. Smith, Molecular pathways: Fibroblast growth factor signaling: A new therapeutic opportunity in cancer. Clin. Cancer Res. 18, 1855-1862 (2012).
43. T. Bachelot, I. Ray-Coquard, C. Menetrier-Caux, M. Rastkha, A. Duc, J. Y. Blay, Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br. J. Cancer 88, 1721-1726 (2003).
44. R. Salgado, S. Junius, I. Benoy, P. Van Dam, P. Vermeulen, E. Van Marck, P. Huget, L. Y. Dirix, Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int. J. Cancer 103, 642-646 (2003).
45. G. J. Zhang, I. Adachi, Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res. 19, 1427-1432 (1999).
46. D. L. Shattuck, J. K. Miller, K. L. Carraway III, C. Sweeney, Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res. 68, 1471-1477 (2008).
47. ClinicalTrials.gov, http://clinicaltrials.gov [accessed 28 August 2013].
48. B. Weigelt, J. Downward, Genomic determinants of PI3K pathway inhibitor response in cancer. Front. Oncol. 2, 109 (2012).
49. J. Baselga, I. Bradbury, H. Eidtmann, S. Di Cosimo, E. de Azambuja, C. Aura, H. Gómez, P. Dinh, K. Fauria, V. Van Dooren, G. Aktan, A. Goldhirsch, T. W. Chang, Z. Horvath, M. Coccia-Portugal, J. Domont, L. M. Tseng, G. Kunz, J. H. Sohn, V. Semiglazov, G. Lerzo, M. Palacova, V. Probachai, L. Pusztai, M. Untch, R. D. Gelber, M. Piccart-Gebhart, on behalf of the NeoALTTO Study Team, Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, phase 3 trial. Lancet 379, 633-640 (2012).
50. C. E. Geyer, J. Forster, D. Lindquist, S. Chan, C. G. Romieu, T. Pienkowski, A. Jagiello-Gruszfeld, J. Crown, A. Chan, B. Kaufman, D. Skarlos, M. Campone, N. Davidson, M. Berger, C. Oliva, S. D. Rubin, S. Stein, D. Cameron, Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355, 2733-2743 (2006).
51. A. Roidl, H. J. Berger, S. Kumar, J. Bange, P. Knyazev, A. Ullrich, Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation. Clin. Cancer Res. 15, 2058-2066 (2009).
52. M. Moschetta, A. Basile, A. Ferrucci, M. A. Frassanito, L. Rao, R. Ria, A. G. Solimando, N. Giuliani, A. Boccarelli, F. Fumarola, M. Coluccia, B. Rossini, S. Ruggieri, B. Nico, E. Maiorano, D. Ribatti, A. M. Roccaro, A. Vacca, Novel targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myeloma. Clin. Cancer Res. 19, 4371-4382 (2013).
53. H. Korkaya, G. I. Kim, A. Davis, F. Malik, N. L. Henry, S. Ithimakin, A. A. Quraishi, N. Tawakkol, R. D'Angelo, A. K. Paulson, S. Chung, T. Luther, H. J. Paholak, S. Liu, K. A. Hassan, Q. Zen, S. G. Clouthier, M. S. Wicha, Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol. Cell 47, 570-584 (2012).
54. D. C. Smith, M. R. Smith, C. Sweeney, A. A. Elfiky, C. Logothetis, P. G. Corn, N. J. Vogelzang, E. J. Small, A. L. Harzstark, M. S. Gordon, U. N. Vaishampayan, N. B. Haas, A. I. Spira, P. N. Lara Jr., C. C. Lin, S. Srinivas, A. Sella, P. Schöffski, C. Scheffold, A. L. Weitzman, M. Hussain, Cabozantinib in patients with advanced prostate cancer: Results of a phase II randomized discontinuation trial. J. Clin. Oncol. 31, 412-419 (2013).
55. T. K. Choueiri, U. Vaishampayan, J. E. Rosenberg, T. F. Logan, A. L. Harzstark, R. M. Bukowski, B. I. Rini, S. Srinivas, M. N. Stein, L. M. Adams, L. H. Ottesen, K. H. Laubscher, L. Sherman, D. F. McDermott, N. B. Haas, K. T. Flaherty, R. Ross, P. Eisenberg, P. S. Meltzer, M. J. Merino, D. P. Bottaro, W. M. Linehan, R. Srinivasan, Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J. Clin. Oncol. 31, 181-186 (2013).
56. D. M. French, B. C. Lin, M. Wang, C. Adams, T. Shek, K. Hötzel, B. Bolon, R. Ferrando, C. Blackmore, K. Schroeder, L. A. Rodriguez, M. Hristopoulos, R. Venook, A. Ashkenazi, L. R. Desnoyers, Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS One 7, e36713 (2012).
57. K. Sato, M. Tsuchiya, J. Saldanha, Y. Koishihara, Y. Ohsugi, T. Kishimoto, M. M. Bendig, Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res. 53, 851-856 (1993).
58. P. M. Voorhees, R. F. Manges, P. Sonneveld, S. Jagannath, G. Somlo, A. Krishnan, S. Lentzsch, R. C. Frank, S. Zweegman, P. W. Wijermans, R. Z. Orlowski, B. Kranenburg, B. Hall, T. Casneuf, X. Qin, H. van de Velde, H. Xie, S. K. Thomas, A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br. J. Haematol. 161, 357-366 (2013).
59. I. R. Hutcheson, J. M. Knowlden, S. E. Hiscox, D. Barrow, J. M. Gee, J. F. Robertson, I. O. Ellis, R. I. Nicholson, Heregulin β1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. Breast Cancer Res. 9, R50 (2007).
60. J. T. Garrett, C. R. Sutton, R. Kurupi, C. U. Bialucha, S. A. Ettenberg, S. D. Collins, Q. Sheng, J. Wallweber, L. Defazio-Eli, C. L. Arteaga, Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110a inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers. Cancer Res. 10.1158/0008-5472.CAN-13-1191 (2013).
61. B. L. Millard, M. Niepel, M. P. Menden, J. L. Muhlich, P. K. Sorger, Adaptive informatics for multifactorial and high-content biological data. Nat. Methods 8, 487-493 (2011).
62. M. Pérez-Enciso, M. Tenenhaus, Prediction of clinical outcome with microarray data: A partial least squares discriminant analysis (PLS-DA) approach. Hum. Genet. 112, 581-592 (2003).
63. I. H. Witten, E. Frank, M. A. Hall, Data Mining (Morgan Kaufmann Publishers, Burlington, MA, ed. 3, 2011), chap. 5.3.
64. A. Varma, R. Simon, Bias in error estimation when using cross-validation for model selection. BMC Bioinformatics 7, 91 (2006).